Showing results (41-50 of 44) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Cancer Immunology Research|October 12, 2021
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 AgentsHikmat H Assi, Chihunt Wong, Kimberly A Tipton, et al.Science Translational Medicine|October 18, 2013
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic indexLuc R Desnoyers, Olga Vasiljeva, Jennifer H Richardson, et al.Molecular Cancer Therapeutics|June 6, 2022
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug ConjugateShweta Singh, Laura Serwer, Amy DuPage, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.Pageof 5